The present disclosure provides methods and systems for printing a three-dimensional (3D) material. In some examples, a method for printing a 3D biological material comprises providing a media chamber comprising a medium comprising (i) a plurality of cells and (ii) one or more polymer precursors. Next, at least one energy beam may be directed to the medium in the media chamber along at least one energy beam path that is patterned into a 3D projection wherein the x, y, and z dimensions may be simultaneously accessed in accordance with computer instructions for printing the 3D biological material in computer memory, to form at least a portion of the 3D biological material comprising (i) at least a subset of the plurality of cells, and (ii) a polymer formed from the one or more polymer precursors.

A method for 3D printing a patient-specific bone implant having variable density, in various aspects, comprises: (1) providing a thermoplastic polymer composition comprising: (A) between about 20% and about 50% bioactive agent by weight; (B) between about 0.5% and about 10% chemical foaming agent by weight; and (C) balance structural polymer by weight; (2) receiving, by computing hardware, a scan of a bone, the scan comprising at least a 3D image of the bone and radiodensity data for the bone; and (3) causing, by the computing hardware, a 3D printer to form the patient-specific bone implant from the 3D image using the thermoplastic polymer by modifying a 3D printing temperature of the 3D printer during printing of the patient-specific bone implant such that each portion of the patient-specific bone implant is produced at a temperature that corresponds to a desired density defined by the radiodensity data for the bone.

The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.

The present invention is directed to bioresorbable polymers to be used as bone and tissue adhesives. The present invention is also directed to the synthesis of bioresorbable polymeric molecules bearing adhesive moieties and the use of such compounds in methods to glue and stabilize fractured bones and damaged tissues. The present invention is also directed to the use of such compounds as adhesive sealants for applications in wound care. The present invention is also directed to the use of such compounds as biodegradable ink for applications in tissue engineering and 3D printing. The present invention also relates to the use of such compounds as drug delivery platforms.

The present invention utilises 3D printing technology, specifically fused filament fabrication (FFF) 3D printing, to produce solid dosage forms, such as pharmaceutical tablets. The production process utilises novel printing filaments, typically on a spool, which contain the active ingredient. Such active-containing filaments have proved to be extremely robust and the principles outlined in the present disclosure provide access to a variety of viable formulations directly from a 3D printer. This, for the first time, affords a viable means for the in situ (e.g. within a pharmacy) 3D printing of personalised medicines tailored to a patient's needs. The invention also relates to purpose-built software for operating the printing apparatus, as well as local, national and global systems for monitoring the real time operation of a plurality of printing apparatuses to enable facile detection of malfunctions, thereby making regulatory approval viable and facilitating regulatory compliance.

A method of preparing antimicrobial 3D-printed material with antimicrobial agents integrated with the 3D-printed material. The 3D-printed material fabricated with the method of the present disclosure includes antimicrobial agent (s) fully integrated throughout the product and display antimicrobial effect throughout the product, which is resistant to daily wear and tear.

Drug delivery devices having a drug-permeable component and methods of making and using the same are provided. Drug delivery devices include a housing having a first and second wall structures that are adjacent one another and together form a tube defining a drug reservoir lumen. The second wall structure, or both the first wall structure and the second wall structure, are permeable to water, and the first wall structure is impermeable to the drug while the second wall structure is permeable to the drug, such that the drug is releasable in vivo by diffusion through the second wall structure.

A device for occluding a vasculature of a patient including a micrograft having an absorbent polymeric structure with a lumen of transporting blood. The micrograft has a series of peaks and valleys formed by crimping. The occluding device is sufficiently small and flexible to be tracked on a guidewire and/or pushed through a microcatheter to a site within the vasculature of the patient. Delivery systems for delivering the micrografts are also disclosed.

A method for 3D printing a patient-specific bone implant having variable density, in various aspects, comprises: (1) providing a thermoplastic polymer composition comprising: (A) between about 20% and about 50% bioactive agent by weight; (B) between about 0.5% and about 10% chemical foaming agent by weight; and (C) balance structural polymer by weight; (2) receiving, by computing hardware, a scan of a bone, the scan comprising at least a 3D image of the bone and radiodensity data for the bone; and (3) causing, by the computing hardware, a 3D printer to form the patient-specific bone implant from the 3D image using the thermoplastic polymer by modifying a 3D printing temperature of the 3D printer during printing of the patient-specific bone implant such that each portion of the patient-specific bone implant is produced at a temperature that corresponds to a desired density defined by the radiodensity data for the bone.

A three-dimensional (3D) bioprinting method and system are disclosed. The method includes disposing/immersing a printing platform or surface into a first bioink, such as a bioink resin, curing one or more layer of the first bioink resin onto the printing platform or surface, and removing the printing platform or surface from the first bioink resin. The process is repeated with a second bioink resin such that the second bioink resin is cured on top of the one or more layer of first bioink resin, and can be further repeated with a third or even fourth bioink resin. By varying constituents of one or more or each bioink resin (such as living cell type or polymer), complex, multilayered tissues can be engineered. A system capable of performing the method is also disclosed.